The clinical development of FLT3 inhibitors in acute myeloid leukemia

Abstract excerpt

INTRODUCTION: Activating mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur at high frequency in acute myeloid leukemia (AML), being detected in > 30% of patients at diagnosis and carrying a profound negative prognostic impact. The development of effective small molecule inhibitors of FLT3 has been the focus of an intensive international research effort in recent years. AREAS COVERED: The published...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Chronic Myeloid Leukemia Treatments
• Share to Microtubule and mitosis dynamics